NAMSW
NewAmsterdam Pharma Company NV - Warrants (15/11/2027) (NAMSW)
NASDAQ • $28.00+32.39%
- Symbol
- NAMSW
- Exchange
- NASDAQ
- Sector
- Industry
- Price
- $28.00
- Daily Change
- +32.39%
- Market Cap
- N/A
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $29.99
- 52W Low
- $7.16
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.03
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Company websiteResearch NAMSW on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.